A 32-year-old man, with a medical history notable only for severe hypertension, was referred to our hospital for hydrocephaly, secondary to a voluminous, hypervascularized, right tympanic tumour encasing the jugular vein and extending to the posterior fossa (Fig. 1A) .
MOTS CLÉS
Cardiomyopathie hypertensive ; Paragangliome ; Fibrose cardiaque A 32-year-old man, with a medical history notable only for severe hypertension, was referred to our hospital for hydrocephaly, secondary to a voluminous, hypervascularized, right tympanic tumour encasing the jugular vein and extending to the posterior fossa (Fig. 1A) .
On admission, the patient was dyspnoeic. Blood pressure was 180/93 mmHg and heart rate was 117 beats/min. Plasma brain natriuretic protein concentration was 2200 pg/mL. Echocardiography showed left ventricular (LV) dilatation (end-diastolic diameter 70 mm) and non-obstructive global LV hypertrophy (LV mass index 200 g/m 2 ). LV ejection fraction was 30%. These findings were confirmed by magnetic resonance imaging (MRI; Videos 1 and 2), which also demonstrated cardiac fibrosis (Fig. 2) . Because of the presence of both a tumour and hypertrophic cardiomyopathy, metaiodobenzylguanidine (MIBG) and octreotide scintigraphy were performed. These showed high fixation of the tumour, consistent with a paraganglioma (Fig. 1B) . No other tumour foci were identified. Urine analysis confirmed catecholamine levels five to 10 times normal values and genetic testing demonstrated a characteristic mutation for paraganglioma (SDHC gene).
Unfortunately, because of the location and extensive size of the tumour, only palliative treatment for hydrocephaly with a ventriculoperitoneal shunt, and medical therapy for cardiomyopathy with alpha-and beta-adrenergic blockers, were pursued. Genetic screening was proposed to the patient's family.
The prevalence of paraganglioma is one in 30,000; 30% of patients have a genetic substrate and 10% of tumours secrete catecholamines. The diagnosis is established by MIBG or octreotide scintigraphy; biopsies are not indicated. MRI and computed tomography determine tumour extension and vascularization to guide treatment: embolization, surgery and/or metabolic radiotherapy. Severe hypertension in a young subject, especially if associated with cardiac function impairment and hypertrophy, justifies exhaustive investigations looking for an extracardiovascular aetiology, whereas any patient with a known tumour such as paraganglioma or pheochromocytma should undergo complete cardiac examination before any surgical treatment.
